title: [Premenstrual dysphoric disorder: approach and treatment].
abstract: The premenstrual dysphoric disorder corresponds to a severe form of the premenstrual syndrome that mainly shows psychiatric symptoms. The incidence is about 3 to 8% of women in the reproductive age. The essential characteristics are depressive mood, a marked anxiety, emotional instability, and decrease of activity, appearing during the luteal phase and ceasing in the follicular phase of the menstrual cycle. Several factors are implied in the pathogenesis of this disorder. Neurobiological and psychobiologic effects concerning the metabolism of serotonin and the melatonin play a role. Several therapies were proposed. The most effective treatment seem to be the selective inhibitors of the of serotonin reuptake.
authors.affiliation: Clinique de stérilité et endocrinologie gynécologique, département de gynécologie et obstétrique, hôpitaux universitaires de Genève, 32, boulevard de la Cluse, 1211 Genève, 14, Suisse. francesco.bianchi-dimicheli@hcuge.ch
authors.forename: F
authors.initials: F
authors.lastname: Bianchi-Demicheli
authors.forename: F
authors.initials: F
authors.lastname: Lüdicke
authors.forename: A
authors.initials: A
authors.lastname: Campana
mesh_terms: D000339:Affect; D001007:Anxiety; D003863:Depression; D005260:Female; D006801:Humans; D008183:Luteal Phase; D008550:Melatonin / Q000378:metabolism; D011293:Premenstrual Syndrome / Q000175:diagnosis / Q000209:etiology / Q000523:psychology* / Q000628:therapy*; D012701:Serotonin / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
chemical_list: D008550:Melatonin; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors